Aro is a biotechnology company focused on the research and development of a new generation of protein biologics called Centyrins. The company is developing a wholly-owned pipeline of Centyrins for oncology and immunology, and is working with leaders in the industry on leveraging Centyrins for delivery of a variety of drug payloads, including nucleic acid drugs for a diverse set of diseases. For more information, visit www.arobiotx.com.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/11/18 | $13,000,000 | Venture | ||
| 01/05/21 | $88,000,000 | Series A |
BioMotiv BVF Partners Cowen Healthcare Investments  HealthCap Ionis Pharmaceuticals Johnson & Johnson Innovation Northpond Ventures Ridgeback Capital Management | undisclosed |
| 11/28/23 | $41,500,000 | Series B |
BVF Partners Cowen Healthcare Investments HealthCap Johnson & Johnson Innovation Northpond Ventures | undisclosed |
